AtriCure (ATRC) Reports In-Line Q2 EPS, provides guidance

AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $116.3 million versus the consensus estimate of $116.18 million.

GUIDANCE:

AtriCure sees FY2024 EPS of ($0.74)-($0.82), versus the consensus of ($0.77). AtriCure sees FY2024 revenue of $456-461 million, versus the consensus of $461.9 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• Trump: Will rein things in if we have to, but I will only encourage AI
• Raymond James Reiterates Outperform Rating on Verizon (VZ)